Eton Pharmaceuticals, Inc. (ETON)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (NASDAQ: ETON). Investors who purchased Eton securities are encouraged to obtain additional information and assist the investigation..                                           

The investigation concerns whether Eton has violated federal securities laws.

Investigation Details:

On June 28, 2023, Eton issued a press release “announc[ing] . . . that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) in response to its New Drug Application (NDA) for dehydrated alcohol injection for the treatment of methanol poisoning.  The issues raised in the CRL relate primarily to Chemistry Manufacturing and Controls (CMC).”  On this news, Eton’s stock price fell $0.70 per share, or 17.33%, to close at $3.34 per share on June 28, 2023.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Eton shares, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.  Our firm has recovered hundreds of millions of dollars for investors nationwide. 

Attorney advertising. Prior results do not guarantee similar outcomes.